Lutein and Zeaxanthin Supplementation and Association With Visual Function in Age-Related Macular Degeneration
Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):252-8. doi: 10.1167/iovs.14-15553.
2013 impact factor for Investigative Ophthalmology & Visual Science: 3.661
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...CrimsonpublishersMSOR
The aim of this study was to investigate the long-term effect of selective laser trabeculoplasty in open angle glaucoma patients as a replacement for medical therapy. 64 eyes of 64 primary open angle glaucoma (POAG) patients under therapy with glaucoma drugs and controlled Intra Ocular Pressure (IOP) were reviewed for 36 months. 360o selective laser therapy (SLT) sessions were performed in two sessions and the medical therapy was stopped. The patients were controlled and evaluated postoperatively 1, 3, 6, 12, 24 and 36 months after surgery for glaucoma progression. In 36 (56.3%) of the 64 patients SLT was successful and there was no need to medical treatment at 36th month. In 28 patients (43.7%) medical treatment was started due to IOP rising. In Logistic regression analysis baseline IOP was found to be significantly effective on success rate of SLT (R2: 0.718, p<0.001).
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...CrimsonpublishersMSOR
The aim of this study was to investigate the long-term effect of selective laser trabeculoplasty in open angle glaucoma patients as a replacement for medical therapy. 64 eyes of 64 primary open angle glaucoma (POAG) patients under therapy with glaucoma drugs and controlled Intra Ocular Pressure (IOP) were reviewed for 36 months. 360o selective laser therapy (SLT) sessions were performed in two sessions and the medical therapy was stopped. The patients were controlled and evaluated postoperatively 1, 3, 6, 12, 24 and 36 months after surgery for glaucoma progression. In 36 (56.3%) of the 64 patients SLT was successful and there was no need to medical treatment at 36th month. In 28 patients (43.7%) medical treatment was started due to IOP rising. In Logistic regression analysis baseline IOP was found to be significantly effective on success rate of SLT (R2: 0.718, p<0.001).
A great deal is happening in lupus-related research. This presentation will update participants on recent research developments and their impact on those affected by lupus. Dr. Petri will provide an overview of current lupus research and the prospects for the future of lupus treatments. Learn how to better manage your lupus and make knowledgeable decisions regarding your treatment plan.
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasaddrsomduttprasad
My Presentation at the 29th Annual Meeting of APACRS 2016 held from July 27-30, 2016 at Bali Dua Convention Center, Bali, Indonesia. Visit http://bit.ly/1ShlIdD for event details and video of the presentation.
Profile of secondary glaucoma cases in a tertiary eye care centre.iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
PRA Insights Report: Alzheimer's Disease ResearchEmma Whieldon
This PRA Insights report focusing on Alzheimer’s disease research was compiled from survey data gathered at the 2017 Alzheimer’s Association International Conference (AAIC). The aim of the survey was to gather insight on clinical development and the future of research in Alzheimer’s disease from pharma and biotech, academic researchers, next generation investigators, clinicians and the care research community involved in the prevention and treatment of Alzheimer’s disease and other dementias.
Age Related Macular Degeneration- Update with Case Studiespresmedaustralia
Eyelea has being introduced in November 2012. It is expected to be the first choice treatment for Neovascular AMD (instead of Lucentis). This talk discusses the reasons for this change.
A great deal is happening in lupus-related research. This presentation will update participants on recent research developments and their impact on those affected by lupus. Dr. Petri will provide an overview of current lupus research and the prospects for the future of lupus treatments. Learn how to better manage your lupus and make knowledgeable decisions regarding your treatment plan.
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasaddrsomduttprasad
My Presentation at the 29th Annual Meeting of APACRS 2016 held from July 27-30, 2016 at Bali Dua Convention Center, Bali, Indonesia. Visit http://bit.ly/1ShlIdD for event details and video of the presentation.
Profile of secondary glaucoma cases in a tertiary eye care centre.iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
PRA Insights Report: Alzheimer's Disease ResearchEmma Whieldon
This PRA Insights report focusing on Alzheimer’s disease research was compiled from survey data gathered at the 2017 Alzheimer’s Association International Conference (AAIC). The aim of the survey was to gather insight on clinical development and the future of research in Alzheimer’s disease from pharma and biotech, academic researchers, next generation investigators, clinicians and the care research community involved in the prevention and treatment of Alzheimer’s disease and other dementias.
Age Related Macular Degeneration- Update with Case Studiespresmedaustralia
Eyelea has being introduced in November 2012. It is expected to be the first choice treatment for Neovascular AMD (instead of Lucentis). This talk discusses the reasons for this change.
Computer Vision Syndrome (CVS) is the general term used to describe a variety of vision related symptoms that may be aggravated by regular use of a computer for two or more hours a day
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.JASHU JASWANTH
In this ppt , you can learn how to reduce the computer eye strain. and the topics i covered was
INTRODUCTION
SYMPTOMS
CAUSES
CONVENTIONAL TREATMENT
SELF HELP FOR COMPUTER EYE STRAIN
SOFTWARE
and most importantly you can see the software which is more helpful to reduce eye strain.
and you can see the link to download , then add interface of the website.
Presentation made May 13, 2015 at live webinar titled Computational Modeling—Will it Rescue AD Clinical Trials? and hosted by Alzforum - http://www.alzforum.org/webinars/computational-modeling-will-it-rescue-ad-clinical-trials
This presentation focusses on the importance of diagnostic biomarkers for Alzheimer's disease. MRI, amyloid PET and CSF biomarkers are discussed in detail.
This presentation by Gavin Giovannoni looks at the new treatment paradigm for MS. It includes: arguments for early treatment in multiple sclerosis, the effect of MS on quality of life and whether highly-effective treatments stabilise MS.
It was presented at the MS Trust Annual Conference in November 2013.
Diabetic retinopathy management an advanced approach gonzalezDiopsys, Inc.
Patients with diabetic retinopathy can benefit from full field flicker electroretinography (ffERG or ficker ERG) vision testing, which provides objective, functional information about global retinal health.
Original publication: http://info.diopsys.com/blog/diabetic-retinopathy-management
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...rowala30
Alka magic plan 1350 -we deliver alkaline water at your door step and you can make handsome money by referral programme
we also help and provide systematic guideline to setup 1000 lph alkaline water plant
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
1. Lutein and Zeaxanthin Supplementation and
Association With Visual Function in Age-
Related Macular Degeneration
Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):252-8. doi: 10.1167/iovs.14-15553.
2013 impact factor for Investigative Ophthalmology & Visual Science: 3.661
2. Introduction
• Age-related macular degeneration (AMD) is a progressively degenerative
disease at the central area of the retina, which results in severe visual
impairment.
• It is the leading cause of irreversible blindness among people aged over 65 in
developed countries.
• With growing longevity, the number of AMD patients is likely to double in 2010
to 2050 in the United States, and this disease is becoming a crucial issue that
threatens public health in the aging population.Therefore, it is urgent to find
feasible interventions to decrease the visual impairment for AMD patients, and
ultimately reduce the burden of this disease.
• Although the exact pathogenesis of AMD remains incompletely understood,
light-initiated oxidative damage and the reduction of macular pigment (MP)
are hypothesized to be the putative mechanisms involved in the disease.
3. • The xanthophyll carotenoids, lutein (L) and zeaxanthin (Z), are concentrated
at the central fovea of the macula and compose the macular pigment. They are
believed to protect the macular region from photo-oxidative injury by
scavenging reactive oxygen species and filtering blue light, which indicates that
these carotenoids may play a role in improving visual function, especially for
AMD patients
From:JAMA Ophthalmol. 2013; 131: 564–572. ;Invest Ophthalmol Vis Sci. 2011; 52: 3934–3942
• Previous epidemiologic studies have shown that higher-level dietary intake of
L and Z was associated with decreased AMD risk and less visual
impairment.
From:Arch Ophthalmol. 2011; 129: 758–766.:AREDS Report No. 22. Arch Ophthalmol. 2007; 125: 1225–1232.
• Several intervention studies suggested that visual function of AMD patients was
improved by L or/and Z supplementation but others still failed to find such
results.
• Therefore, we conducted a meta-analysis of randomized controlled trials
(RCTs) to evaluate the visual performance in AMD with L and Z
supplementation.
Introduction
4. • Systematic literatures up to April 2014 on PubMed, EMBASE, Web of Science,
and Cochrane Library database were searched.
• Key word: Lutein (L), zeaxanthin (Z), xanthophyll, carotenoids and visual
function, visual performance, visual acuity (VA), vision, contrast sensitivity (CS),
glare sensitivity (GS), AMD, age-related maculopathy, neovascular AMD,
exudative AMD, choroidal neovascularization, and geographic atrophy
Study Selection
1. Only studies fulfilling the following criteria were included in the meta-
analysis: (1) eligible studies were limited to RCTs, (2) patients were
diagnosed as AMD and randomized to receive L or/and Z or placebo, and
(3) the outcome of interest was visual function variables, including VA, CS,
glare recovery time (GRT), and the score of Visual Function
Questionnaire (VFQ).
2. If multiple articles were published from the same study, only the last
published report was selected for analysis, and the previous could
be reviewed as supplementations for missing data where applicable.
Methods
5. Data Extraction and Study Quality Assessment:
- The study characteristics recorded were as followings: name of first author, year of publication,
duration of intervention, characteristics of patients (age, sex), the mean dosage of L or/and Z
supplements, outcome measurements, and corresponding assessment methods. For intervention and
placebo groups in each trial, information for the number of patients in each group, the mean and
corresponding SD 。
-The quality of each study included was assessed by the Jadad score, a 5-point study quality
assessment instrument and Studies that gained over a 3 Jadad score were considered to be
categorized as high quality.
Statistical Analysis
-The principal summary measures were the weighted mean differences (WMDs) and
corresponding 95% confidence intervals (CIs).
-The presence of statistically significant heterogeneity was evaluated by conducting Q tests; and
the extent of the observed heterogeneity was assessed by the I2 statistic.
-Sensitivity analyses were conducted to determine the robustness of our conclusions
-Stratified analyses were performed to explore the source of heterogeneity among variables,
Methods
6. • The search strategy yielded 496 citations in total. Among these citations, 441
were excluded after abstract review.
-The excluded studies contained duplicate publications, review articles, non-
RCTs, and studies without original human research.
-On more detailed evaluation, 47 citations were excluded for the following
reasons: duplicate publication, no outcomes suitable for the meta-analysis, lack of a
placebo group, no means or SDs included in the publication.
-The remaining eight studies met the inclusion criteria and were included in this
meta-analysis.
Result
8. Forest plot showing the efficacy of lutein and zeaxanthin
supplements on VA for patients with AMD.
logMAR
9. • The regression models showed
that a linear improvement in VA
was related to the increase in the
dosage of these carotenoids
supplement (r = −0.52, P = 0.03)
• In the dose-response meta-
analysis, each 1mg/day
increase in these carotenoids
supplementation was associated
with a 0.003 statistically
significant reduction in
logMAR levels.
10. Stratified Analysis for the
Lutein or/and Zeaxanthin
Supplements Effect on VA
across the Assessed
RCTs
11. • In the CS comparisons
between the intervention
groups and placebo
groups, significant
postintervention
increase was found at all
four spatial frequencies
(WMD ranging from 0.08–
0.18; all P < 0.05).
• The result of dose-
response analysis
showed that CS improved
0.010, 0.007, and 0.006 at
3, 6, and 12
cycles/degree
respectively, due to a
1mg/day increase in L
and Z supplement.
12.
13. The Relationship Between the Change in MPOD
and Visual Outcomes
• Correlation analysis showed that VA was markedly improved with
the postintervention increase in MPOD (r = −0.58, P = 0.02).
• Additionally, CS at 12 cycles/degree was positively associated with
MPOD augmentation (r = 0.94, P < 0.001),
• Furthermore, the increment in MPOD was not related to the
postintervention decrease in GRT (P > 0.05).
14. Discussion
• Bian et al. indicated that incubation of the N-retinylidene-N-
retinylethanolamine (A2E)-containing RPE with L or Z could
significantly attenuate the photooxidation-induced
inactivation of the proteasome.
• Results from animal experiments showed that 6-month
supplementation with xanthophyll carotenoids in quails could
markedly decrease the level of photoreceptor apoptosis in
response to light injury.38
• The potential mechanism of action of these carotenoids was also
thought to involve in the reduction of chromatic aberration by
absorbing the blue light.
15. Discussion
First, there were relatively few studies included in this meta-analysis, which might
have limited power to detect statistical differences in the individual end points with L
or/and Z supplementation reliably.
• we examined the totality of the evidence by pooling the data from all available RCTs,
for the findings from these studies were less likely to be restricted compared with
observational studies
• All studies included were considered as high quality, which might enhance the
reliability of our finding.
Second, due to the relatively shorter intervention duration in most studies and the
lack of follow-up after intervention cessation, a question remained unanswered that
whether these carotenoids had long-term beneficial effects on visual function or not.
• Nevertheless, a significant effect on VA improvement after these carotenoids
supplementation was found in the present study. So it is promising that visual
function will be improved markedly by L and Z supplementation for AMD patients.
16. Conclusion
• This meta-analysis demonstrated significant benefits of L and Z
supplementation to VA and CS for AMD patients, which was positively
associated with MPOD elevation. However, as the relatively smaller number
of RCTs included may limit the power of this study, further large longer-
term RCTs are required to confirm the findings of this review, and to
determine the mechanism of association between supplementation status and
outcomes.
19. • Third, majority of the studies were predominantly performed in Western
participants, and the generalizability of the meta-analyses might be
limited to a wider population.
• Fourth, our results might be affected by some potential confounding
factors, although the variables in all the researches incorporated had
been adjusted, and identified confounding in each study was also
effectively eliminated by randomly allocating patients.
• Finally, publication bias could not be ruled out completely even though
it was not detectable in the current analysis.
Discussion